Tisotumab Vedotin Safety and Tolerability in Clinical Practice: Managing Adverse Events

Tisotumab vedotin-tftv, an antibody-drug conjugate indicated for the treatment of adult patients with recurrent or metastatic cervical cancer with disease progression on or after chemotherapy, demonstrated clinically meaningful and durable responses with a manageable safety profile in the pivotal ph...

Descripción completa

Detalles Bibliográficos
Autores principales: Arn, Courtney R., Halla, Kimberly J., Gill, Sally
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Harborside Press LLC 2023
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10062530/
https://www.ncbi.nlm.nih.gov/pubmed/37009403
http://dx.doi.org/10.6004/jadpro.2023.14.2.4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10062530/
https://www.ncbi.nlm.nih.gov/pubmed/37009403
http://dx.doi.org/10.6004/jadpro.2023.14.2.4

Ejemplares similares